Nisha S. Joseph

Long-Term Follow-Up Results of Lenalidomide, Bortezomib, and Dexamethasone Induction Therapy and Risk-Adapted Maintenance Approach in Newly Diagnosed Multiple Myeloma

Nisha S. Joseph, Jonathan L. Kaufman, Madhav V. Dhodapkar et al. · Journal of Clinical Oncology · 2020 · 237 citations · Full text

Medicine, Oncology, Pharmacotherapy +15

Gain of Chromosome 1q is associated with early progression in multiple myeloma patients treated with lenalidomide, bortezomib, and dexamethasone

Timothy M. Schmidt, Benjamin G. Barwick, Nisha S. Joseph et al. · Blood Cancer Journal · 2019 · 165 citations · Full text

Medicine, Hematology, Oncology +15

Clinical efficacy of daratumumab, pomalidomide, and dexamethasone in patients with relapsed or refractory myeloma: Utility of re‐treatment with daratumumab among refractory patients

Ajay K. Nooka, Nisha S. Joseph, Jonathan L. Kaufman et al. · Cancer · 2019 · 92 citations · Full text

Medicine, Oncology, Pharmacotherapy +17

Venetoclax sensitivity in multiple myeloma is associated with B-cell gene expression

Vikas A. Gupta, Benjamin G. Barwick, Shannon M. Matulis et al. · Blood · 2021 · 81 citations · Full text

Life Sciences, Hematology, Immunology +11

Survival outcomes of patients with primary plasma cell leukemia (pPCL) treated with novel agents

Roberto Mina, Nisha S. Joseph, Jonathan L. Kaufman et al. · Cancer · 2018 · 56 citations · Full text

Medicine, Hematology, Oncology +14